US › Healthcare

Caribou Biosciences Inc (CRBU)

US · Healthcare · Biotechnology

$1.57+4.67%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$2.4M
Revenue YoY
+1.9%
Net profit
$-25.1M
Profit YoY
+37.3%
EPS
$-0.26
EPS estimate
$-0.31
Net margin
-1,046.5%

EPS came in at -0.26 against a street estimate of -0.31 — a beat of 16.1%.

Key statistics

Market cap
$144.8M
Forward P/E
0.0
P/B
1.42
Book value
$1.05
EPS (TTM)
$-1.42
52-week high
$3.54
52-week low
$1.38
50-day MA
$1.81
200-day MA
$1.89
Beta
2.37

Analyst view

Analysts rate Caribou Biosciences Inc a buy (7 buy, 2 hold, 0 sell out of 9) with an average price target of $12.00.

Shareholding

Insiders
8.91%
Institutions
37.20%

Largest institutional holders

FundStake
Pfizer Inc4.73%
Vanguard Capital Management, LLC3.80%
Renaissance Technologies Corp2.61%
Kynam Capital Management, LP2.52%
BlackRock Inc2.16%
Two Sigma Investments LLC1.77%
Bank of America Corp1.31%
Aberdeen Group PLC1.22%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Caribou Biosciences Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.